Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

PBLA Panbela Therapeutics

Watchlist
0.133
+0.013+10.83%
Close 11/25 13:00 ET
0.1330.0000.00%
Post Mkt Price 11/25 16:47 ET
High
0.140
Open
0.126
Turnover
147.33K
Low
0.120
Pre Close
0.120
Volume
1.13M
Market Cap
4.20M
P/E(TTM)
Loss
52wk High
2.400
Shares
31.71M
P/E(Static)
Loss
52wk Low
0.100
Float Cap
3.14M
Bid/Ask %
-40.94%
Historical High
8.800
Shs Float
23.67M
Volume Ratio
4.93
Historical Low
0.100
Dividend TTM
--
Div Yield TTM
--
P/B
-0.51
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
4.77%
Amplitude
16.35%
Avg Price
0.130
Lot Size
1
Float Cap
3.14M
Bid/Ask %
-40.94%
Historical High
8.800
Shs Float
23.67M
Volume Ratio
4.93
Historical Low
0.100
Dividend TTM
--
P/B
-0.51
Dividend LFY
--
Turnover Ratio
4.77%
Amplitude
16.35%
Avg Price
0.130
Lot Size
1
Price Forecast

No Data

News

Comment

No Data

Company Overview More
Panbela Therapeutics, Inc. engages in the development of disruptive therapeutics for medical purposes. It focuses on development programs that target diseases of the pancreas, including pancreatic cancer and pancreatitis. The firm’s product candidate, SBP-101, is a proprietary polyamine analogue designed to induce polyamine metabolic inhibition (PMI), a metabolic pathway of critical importance in multiple tumor types. The company was founded by Michael T. Cullen, Jr. and Thomas X. Neenan on September 21, 2011 and is headquartered in Waconia, MN.
CEO: Dr. Jennifer K Simpson, PhD
Market: NASDAQ
Listing Date: 08/28/2020
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist